MedTrace Logo

A Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic HBV

NCT02751996 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-02-11

No results posted yet for this study

Summary

This is a Phase 2, open-label,randomized, multiple dose, varied administration regimen study with 2 parts (Parts A and B) in Subjects Infected with Chronic Hepatitis B Virus

Conditions

Interventions

DRUG

SB 9200

SB 9200

DRUG

Placebo

DRUG

Tenofovir

Sponsors & Collaborators

  • F-star Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Chelsea Macfarlane · SBP Sr. Director of Clinical Operations

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2020-02-10
Completion
2020-02-10

Countries

  • Canada
  • Hong Kong
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02751996 on ClinicalTrials.gov